Inhibition of abnormal C/ EBPβ / α‐Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease‐like pathology
Aging Cell · 2023
DOI: 10.1111/acel.13958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Aging Cell, 2023. Verfasst von Zefang Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology, School of Medicine, Jinan University, Guangzhou, China. Hauptthemen laut MEDLINE: Neuroblastoma, Parkinson Disease. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Parkinson's disease (PD) is characterized by the formation of Lewy bodies (LBs) in the brain. These LBs are primarily composed of α‐Synuclein (α‐Syn), which has aggregated. A recent report proposes that CCAAT/enhancer‐binding proteins β (C/EBPβ) may act as an age‐dependent transcription factor for α‐Syn, thereby initiating PD pathologies by regulating its transcription. Potential therapeutic approaches to address PD could involve targeting the regulation of α‐Syn by C/EBPβ. This study has revealed that Nrf2, also known as nuclear factor (erythroid‐derived 2)‐like 2 (NFE2L2), suppresses the transcription of C/EBPβ in SH‐SY5Y cells when treated with MPP + . To activate Nrf2, sulforaphane, an Nrf2 activator, was administered. Additionally, C/EBPβ was silenced using C/EBPβ‐DNA/RNA heteroduplex oligonucleotide (HDO). Both approaches successfully reduced abnormal α‐Syn expression in primary neurons treated with MPP + . Furthermore, sustained activation of Nrf2 via its activator or inhibition of C/EBPβ using C/EBPβ‐HDO resulted in a reduction of aberrant α‐Syn expression, thus leading to an improvement in the degeneration of dopaminergic neurons in the substantia nigra pars compacta (SNc) in mouse models induced by 1‐methyl‐4‐phenyl‐1,2,5,6‐tetrahydropyridine (MPTP) and those treated with preformed fibrils (PFFs). The data presented in this study illustrate that the activation of Nrf2 may provide a potential therapeutic strategy for PD by inhibiting the abnormal C/EBPβ/α‐Syn signaling pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology, School of Medicine, Jinan University, Guangzhou, China.
- Guangzhou Key Laboratory of Formula-pattern Research Center, School of Traditional Chinese Medicine, Jinan University, Guangzhou, China.
- Institute of Brain Science and Brain-inspired Research, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China.
ORCID-Profile: Ji-Chun Zhang
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Lin, Z., Huang, L., Cao, Q., Luo, H., Yao, W., & Zhang, J. C. (2023). Inhibition of abnormal C/ EBPβ / α‐Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease‐like pathology. Aging Cell. https://doi.org/10.1111/acel.13958
Vancouver
Lin Z, Huang L, Cao Q, Luo H, Yao W, Zhang JC. Inhibition of abnormal C/ EBPβ / α‐Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease‐like pathology. Aging Cell. 2023. doi:10.1111/acel.13958
BibTeX
@article{Lin2023,
author = {Lin, Zefang and Huang, Lixuan and Cao, Qianqian and Luo, Hanyue and Yao, Wei and Zhang, Ji-Chun},
title = {Inhibition of abnormal C/ EBPβ / α‐Syn signaling pathway through activation of Nrf2 ameliorates Parkinson's disease‐like pathology},
journal = {Aging Cell},
year = {2023},
doi = {10.1111/acel.13958}
}
EUVIMED